Listed

Journey Medical Corp: Form 10-Q for the period ended Sep 30, 2022

Filed with the SEC on Nov 10, 2022 and accepted by EDGAR at Nov 10, 2022, 16:58 ET.

Share

Management's discussion and analysis

As filed, 43,704 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Forward-Looking Statements

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our unaudited condensed consolidated financial statements and the related notes included elsewhere in this Form 10-Q. Our unaudited condensed consolidated financial statements have been prepared in accordance with U.S. GAAP. The following discussion and analysis contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (the “Exchange Act”), including, without limitation, statements regarding our expectations, beliefs, intentions or future strategies. We use words such as “expect,” “anticipate,” “intend,” “believe,” “may,” “plan,” “seek,” “could,” “would,” “should,” “will” or similar language to identify forward-looking statements, but not all-forward-looking statements include these words. All forward-looking statements included in this document are based on information available to us on the date hereof and we assume no obligation to update any such forward-looking statements. For such forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Our business and financial performance are subject to substantial risks and uncertainties. Actual results could differ materially from those projected in, or implied by, the forward-looking statements. In evaluating our business, you should carefully consider the information set forth under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2021 (the “2021 Form 10-K”). As used below, the words “we,” “us” and “our” refer to Journey Medical Corporation and its consolidated subsidiary.

Overview

We are a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. Our current portfolio includes eight branded and three authorized generic prescription drugs for dermatological conditions that are actively marketed in the U.S. We are managed by experienced life science executives with a track record of creating value for their stakeholders and bringing novel medicines to the market, enabling patients to experience increased quality of life and physicians and other licensed medical professionals to provide better care for their patients. We aim to acquire rights to products and product candidates by licensing or otherwise acquiring an ownership interest in, funding the research and development of, and eventually commercializing, dermatological products through our exclusive field sales organization.

On November 16, 2021, we completed an initial public offering (“IPO”) of our Common Stock, which resulted in net proceeds of approximately $30.6 million, after deducting underwriting discounts and other offering costs.

We expect our expenses will increase for the foreseeable future as we pursue business development opportunities, commercialize and market new products and incur additional costs associated with operating as a public company. We believe the impact of inflation on our operations has been minimal. However, continued general inflation, including rising prices in the normal course of business, may negatively impact our operations by increasing our operating expenses. To the extent general inflation results in rising interest rates and has other adverse effects on the market, it may adversely affect our business, financial condition, and results of operations. To date, our business has not been materially impacted by COVID-19; however, depending on the extent of the ongoing pandemic, it is possible that our business, financial condition and results of operations could be materially and adversely affected by COVID-19 in the future. Our cash and cash equivalents balance was $34.9 million at September 30, 2022.

Recent Highlights

Clinical Developments

Building on the results of the Phase 2 clinical study published in December 2021, where DFD-29 demonstrated nearly double the efficacy, when compared to Doxycycline capsules 40 mg, on reducing total inflammatory lesions and Investigator’s Global Assessment treatment success, on March 14, 2022, we dosed the first patient in our Phase 3 clinical trial evaluating DFD-29 (Modified Release Minocycline, 40 mg capsules) for the treatment of Rosacea. The Phase 3 clinical trials encompass two multicenter, randomized, double-blind, parallel-group, active and placebo-controlled clinical trials and will each enroll up to 320 adult patients with moderate to severe papulopustular rosacea (“PPR”). One trial is enrolling patients in the United States and the other is enrolling in the United States and Europe. The patients are being randomized in a 3:3:2 ratio to DFD-29 (Modified Release Minocycline Capsules, 40 mg), Oracea® (Doxycycline capsules, 40 mg) or placebo once daily for 16 weeks. The primary objective of the studies is to evaluate the safety, efficacy and tolerability of DFD-29 compared to placebo for the treatment of PPR. The secondary objective is to evaluate the safety, efficacy and tolerability of DFD-29 compared to Oracea® (Doxycycline capsules 40 mg). As of October 2022, enrollment, in the Phase 3 clinical trials have achieved over 75% enrollment. Looking ahead, we expect to announce topline data from the Phase 3 program in the first half of 2023, with a New Drug Application (“NDA”) filing expected in the second half of 2023.

Critical Accounting Polices and Uses of Estimates

Our discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which we have prepared in accordance with accounting principles generally accepted in the United States. Applying these principles requires our judgment in determining the appropriateness of acceptable accounting principles and methods of application in diverse and complex economic activities. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of revenues, expenses, assets and liabilities, and related disclosure of contingent assets and liabilities. We base our estimates on historical experience and other assumptions that we believe are reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions.

For a discussion of our critical accounting estimates, see the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” section in the 2021 Form 10-K. There were no material changes in our critical accounting estimates or accounting policies from December 31, 2021.

Accounting Pronouncements

During the three-month period ended September 30, 2022, there were no new accounting pronouncements or updates to recently issued accounting pronouncements disclosed in the 2021 Form 10-K that are expected to materially affect the Company’s present or future financial statements.

Smaller Reporting Company Status

We are a “smaller reporting company,” meaning that the market value of our shares held by non-affiliates is less than $700 million and our annual revenue was less than $100 million during the most recently completed fiscal year. We may continue to be a smaller reporting company as long as either (i) the market value of our shares held by non-affiliates is less than $250 million or (ii) our annual revenue was less than $100 million during the most recently completed fiscal year and the market value of our shares held by non-affiliates is less than $700 million. As a smaller reporting company, we may choose to present only the two most recent fiscal years of audited financial statements in our annual reports on Form 10-K, have reduced disclosure obligations regarding executive compensation and certain other matters, and smaller reporting companies are permitted to delay adoption of certain recent new accounting pronouncements.

Results of Operations

The following table summarizes our results of operations for the three-month periods ended September 30, 2022 and 2021:

Comparison of the Three-Month Periods Ended September 30, 2022 and 2021

The following table reflects our net product revenue for the three-month periods ended September 30, 2022 and 2021:

($ in thousands, except per share data)

​ ​ ​ Revenue: ​ ​ ​ ​ ​ ​ Three-Month Periods Ended September 30, 2022 ​ ​ ​ ​ ​ ​ 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Change $% ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Product revenue, net $16,043 $19,610 ​ $(3,567) ​ -18%
Other revenue ​ ​ 73 ​ ​ — ​ ​ 73 ​ 100%
Total revenue ​ ​ 16,116 ​ ​ 19,610 ​ ​ (3,494) ​ -18%
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Operating expenses ​ ​ ​ ​ ​ ​
Cost of goods sold - product revenue ​ 7,221 ​ 11,167 ​ ​ (3,946) ​ -35%
Research and development ​ 2,812 ​ 718 ​ ​ 2,094 ​ 292%
Research and development - licenses acquired ​ — ​ 76 ​ ​ (76) ​ -100%
Selling, general and administrative ​ 15,575 ​ 10,755 ​ ​ 4,820 ​ 45%
Wire transfer fraud loss ​ — ​ 9,540 ​ ​ (9,540) ​ -100%
Total operating expenses ​ 25,608 ​ 32,256 ​ ​ (6,648) ​ -21%
Loss from operations ​ (9,492) ​ (12,646) ​ ​ 3,154 ​ -25%
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Other expense ​ ​ ​ ​ ​ ​ ​
Interest income ​ (3) ​ — ​ ​ (3) ​ 100%
Interest expense ​ ​ 559 ​ ​ 1,373 ​ ​ (814) ​ -59%
Foreign exchange transaction losses ​ ​ 22 ​ ​ — ​ ​ 22 ​ 100%
Change in fair value of derivative liability ​ — ​ 2 ​ ​ (2) ​ -100%
Total other expense ​ 578 ​ 1,375 ​ ​ (797) ​ -58%
Loss before income taxes ​ (10,070) ​ (14,021) ​ ​ 3,951 ​ -28%
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Income tax benefit ​ 10 ​ (3,375) ​ ​ 3,385 ​ -100%
Net Loss ​ $(10,080) ​ $(10,646) ​ $566 ​ -5%

Revenues

Net product revenue

($ in thousands)

​ ​ ​ ​ ​ ​ ​ ​ Three-Month Periods Ended September 30, 2022 ​ ​ ​ 2021 ​ ​ ​ ​ ​ ​ ​ Change $% ​ ​ ​ ​ ​ ​ ​
Qbrexza® ​ $6,265 ​ $6,636 ​ $(371) ​ -6%
Accutane® ​ ​ 4,121 ​ ​ 3,531 ​ ​ 590 ​ 17%
Amzeeq ​ ​ 1,161 ​ ​ — ​ ​ 1,161 ​ 100%
Targadox® ​ ​ 1,168 ​ ​ 5,184 ​ ​ (4,016) ​ -77%
Ximino® ​ 1,773 ​ 2,864 ​ ​ (1,091) ​ -38%
Zilxi ​ ​ 554 ​ ​ — ​ ​ 554 ​ 100%
Exelderm® ​ 1,001 ​ 1,366 ​ ​ (365) ​ -27%
Other branded revenue ​ — ​ 29 ​ ​ (29) ​ -100%
Total net product revenues ​ $16,043 ​ $19,610 ​ $(3,567) ​ -18%

Total net product revenues decreased $3.6 million, or 18%, to $16.0 million for the three-month period ended September 30, 2022, from $19.6 million for the three-month period ended September 30, 2021. The decrease is primarily driven by a decrease in the net product revenue of Targadox and its authorized generic, as a result of continued generic competition. In addition, net product revenues of Ximino and its authorized generic, as well as Exelderm and its authorized generic, have been negatively impacted by contract manufacturer product shortages. These shortages were resolved in the third quarter of 2022. We expect sales of Ximino and Exelderm to continue to normalize through the end of the year, generating higher net product revenues in future quarters. Offsetting, in part, the above decreases in net product revenues is net revenue growth of $0.5 million compared to the year-ago period from the continued growth of Accutane. We launched Accutane at the end of the first quarter of 2021. In addition, another partially offsetting increase in product revenue during the three-month period ended September 20, 2022 is driven by incremental net revenues as a result of our newly acquired and launched products, Amzeeq and Zilxi. The above table includes the authorized generic product within the line items for Targadox, Ximino and Exelderm.

Other revenue

Other revenue for the three-month period ended September 30, 2022 reflects a $73,000 royalty payment from the Company’s exclusive out-licensing partner in Japan, Maruho Co., Ltd (“Maruho”) paid in connection with Maruho’s sales of Rapifort® Wipes 2.5% in Japan.

Gross-to-Net Sales Accruals

We record gross-to-net sales accruals for chargebacks, distributor service fees, prompt pay discounts, sales returns, coupons, managed care rebates, government rebates, and other allowances customary to the pharmaceutical industry. For a discussion of our gross-to-net sales accruals, see “Critical Accounting Estimates and Significant Accounting Policies” in the 2021 Form 10-K

Gross-to-net sales accruals and the balance in the related allowance accounts for the three-month periods ended September 30, 2022 and 2021 were as follows:

($’s in thousands)

​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Chargebacks and Distributor Service Fees ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Returns ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Coupons ​ ​ ​ ​ ​ ​ ​ ​ Managed Care Rebates ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Gov’t Rebates ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total
Balance as of June 30, 2022 ​ $1,400 ​ $2,727 ​ $2,499 ​ $3,191 ​ $1,218 ​ $11,035
Current provision related to sales in the current period ​ 2,643 ​ 1,706 ​ 25,801 ​ 6,897 ​ 639 ​ 37,686
Checks/credits issued to third parties ​ (2,625) ​ (1,471) ​ (26,348) ​ (6,339) ​ (928) ​ (37,711)
Reclassifications between liability accounts ​ — ​ — ​ — ​ — ​ — ​ —
Balance as of September 30, 2022 ​ $1,418 ​ $2,962 ​ $1,952 ​ $3,749 ​ $929 ​ $11,010

($’s in thousands)

​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Chargebacks and Distributor Service Fees ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Returns ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Coupons ​ ​ ​ ​ ​ ​ ​ ​ Managed Care Rebates ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Gov’t Rebates ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total
Balance as of June 30, 2021 ​ $— ​ $2,099 ​ $17,527 ​ $1,082 ​ $— ​ $20,708
Current provision related to sales in the current period ​ ​ — ​ ​ 1,946 ​ ​ 37,227 ​ ​ 2,797 ​ ​ 803 ​ ​ 42,773
Checks/credits issued to third parties ​ ​ — ​ ​ (393) ​ ​ (48,197) ​ ​ (1,646) ​ ​ (163) ​ ​ (50,399)
Balance as of September 30, 2021 ​ $— ​ $3,652 ​ $6,557 ​ $2,233 ​ $640 ​ $13,082

Our provision for product returns was $3.0 million at September 30, 2022, compared to $2.7 million at June 30, 2022. The increase is primarily due to an increase in return experience from June 30, 2022.

Our provision for coupons was $2.0 million at September 30, 2022 compared to $2.5 million at June 30, 2022. The decrease is primarily due to a decrease in redemptions, driven by lower sales for the period specifically for Targadox, as a result of continued generic competition.

Our provision for managed care rebates was $3.7 million at September 30, 2022 compared to $3.2 million at June 30, 2022. The increase is primarily due to increased rebate utilization for our Qbrexza product.

The provision for government rebates was $0.9 million at September 30, 2022 compared to $1.2 million at June 30, 2021. The decrease is primarily due a decrease in Medicaid as a result of decreased sales for the period.

Cost of Goods Sold

Cost of goods sold decreased by $3.9 million, or 35%, to $7.2 million for the three-month period ended September 30, 2022, from $11.2 million for the three-month period ended September 30, 2021. The decrease is primarily due to a $2.1 million decrease in the product royalties we are required to pay as a result of a reduction in the royalty percentage paid to Qbrexza by 10 percentage points. Also contributing to the reduction in royalty expense is the lower sales of Targadox as a result of generic competition in the three-month period ended September 30, 2022 compared to the year-earlier period. In addition, the three-month period ended September 30, 2021 included an inventory step-up of $3.0 million for inventory units sold related to the acquired finished goods of Qbrexza® in 2021. Offsetting, in part, the above decreases are increases in cost of goods sold related to higher amortization of licenses of approximately $0.4 million, and higher freight, testing and product validation costs of approximately $0.7 million from our newly acquired and launched products, Amzeeq and Zilxi (acquired in January 2022) and a $0.1 million increase in FDA manufacturing fees from the prior-year quarter.

Research and Development

Research and Development expense increased to $2.8 million for the three-month period ended September 30, 2022, from $0.7 million for the three-month period ended September 30, 2021. The increase is related to clinical trial expenses to develop our DFD-29 product, for which dosing began in March 2022. We expect these expenses to increase as additional patients are enrolled into the two Phase 3 trials as well as the other associated cost of the development program.

Research and Development - licenses acquired

Research and development - licenses acquired decreased $76,000, or 100%, from the three-month period ended September 30, 2021. The three-month period ended September 30, 2021 reflects a contingent license payment from the acquisition of our development stage asset from DRL.

Selling, General and Administrative

Selling, general and administrative expenses increased $4.8 million, or 45%, to $15.6 million for the three-month period ended September 30, 2022, compared to $10.8 million for the three-month period ended September 30, 2021. The increase is primarily attributable to the expansion of our salesforce, marketing expenses related to the expanded product portfolio of our four products, as well as additional headcount costs, including non-cash stock compensation expenses, and compliance and other professional fees associated with being a public company.

Interest Expense

Interest expense decreased $0.8 million to $0.6 million for the three-month period ended September 30, 2022, from $1.4 million for the three-month period ended September 30, 2021. The prior year quarter includes dividends and interest on our convertible preferred shares that converted into common stock upon the closing of our IPO in November 2021.

Income tax benefit

For the three-month period ended September 30, 2022, income taxes reflected an income tax expense of $10,000. For the three-month period ended September 30, 2021, income taxes reflected an income tax benefit of $3.4 million. The change in our income tax benefit from the year-ago period is due to changes in unfavorable permanent book-tax differences and a full valuation allowance against the Company’s deferred tax.

The following table summarizes our results of operations for the nine-month periods ended September 30, 2022 and 2021:

Comparison of the Nine-Month Periods Ended September 30, 2022 and 2021

($in thousands, except per share data)

​ ​ ​ Revenue: ​ ​ ​ ​ ​ Nine-Month Periods Ended September 30, 2022 ​ ​ ​ ​ ​ 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ Change $% ​ ​ ​ ​ ​ ​ ​
Product revenue, net ​ $55,074 ​ $45,617 ​ $9,457 21%
Other revenue ​ 2,629 ​ — ​ 2,629 100%
Total revenue ​ 57,703 ​ 45,617 ​ 12,086 26%
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Operating expenses ​ ​ ​ ​
Cost of goods sold - product revenue ​ 23,057 ​ 22,559 ​ 498 2%
Research and development ​ 6,687 ​ 747 ​ 5,940 795%
Research and development - licenses acquired ​ — ​ 13,819 ​ (13,819) -100%
Selling, general and administrative ​ 45,481 ​ 24,776 ​ 20,705 84%
Wire transfer fraud loss ​ ​ — ​ ​ 9,540 ​ ​ (9,540) ​ -100%
Total operating expenses ​ 75,225 ​ 71,441 ​ 3,784 5%
Loss from operations ​ (17,522) ​ (25,824) ​ 8,302 -32%
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Other expense ​ ​ ​ ​
Interest income ​ (10) ​ — ​ (10) 100%
Interest expense ​ 1,402 ​ 2,936 ​ (1,534) -52%
Foreign exchange transaction losses ​ ​ 22 ​ ​ — ​ ​ 22 ​ 100%
Change in fair value of derivative liability ​ — ​ 184 ​ (184) -100%
Total other expense ​ 1,414 ​ 3,120 ​ (1,706) -55%
Loss before income taxes ​ (18,936) ​ (28,944) ​ 10,008 -35%
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Income tax benefit ​ 50 ​ (6,701) ​ 6,751 -101%
Net Loss ​ ​ (18,986) ​ ​ (22,243) ​ ​ 3,257 -15%

Revenues

Net product revenue

The following table reflects our net product revenue for the nine-month periods ended September 30, 2022 and 2021:

($ in thousands)

​ ​ ​ ​ ​ ​ ​ Nine-Month Periods Ended September 30, 2022 ​ ​ ​ 2021 ​ ​ ​ ​ ​ ​ Change $% ​ ​ ​ ​ ​
Qbrexza® ​ $19,752 ​ $11,204 ​ $8,548 76%
Accutane® ​ 14,228 ​ 5,672 ​ 8,556 151%
Amzeeq ​ 5,892 ​ — ​ 5,892 100%
Targadox® ​ 6,558 ​ 18,110 ​ (11,552) -64%
Ximino® ​ 3,775 ​ 6,277 ​ (2,502) -40%
Zilxi ​ 1,851 ​ — ​ 1,851 100%
Exelderm® ​ 3,018 ​ 4,319 ​ (1,301) -30%
Other branded revenue ​ — ​ 35 ​ (35) -100%
Total net product revenues ​ $55,074 ​ $45,617 ​ $9,457 21%

Total net product revenues increased $9.5 million, or 21%, to $55.1 million for the nine-month period ended September 30, 2022, from $45.6 million for the nine-month period ended September 30, 2021. Our revenue growth over the prior-year period is primarily due to incremental revenues from Qbrexza, acquired and launched during the second quarter of 2021, and the revenue growth of Accutane, launched at the end of the first quarter of 2021. In addition, another contributor to the increase compared to the prior-year period is driven by incremental net revenues from our newly acquired and launched products, Amzeeq and Zilxi (acquired in January 2022). Offsetting, in part, the increases above is a decrease in the net product revenue of Targadox and its authorized generic primarily as a result of continued generic competition. In addition, net product revenues of Ximino and its authorized generic, and Exelderm and its authorized generic, have been negatively impacted by contract manufacturer product shortages. These shortages were resolved in the third quarter of 2022. We expect sales of Ximino and Exelderm to continue to normalize through the end of the year, generating higher net product revenues in future quarters. The above table includes the authorized generic product within the line items for Targadox, Ximino and Exelderm.

Other revenue

The nine-month period ended September 30, 2022 includes a net $2.5 million milestone payment from Maruho. In January 2022, Maruho received manufacturing and marketing approval in Japan for Rapifort® Wipes 2.5%, triggering the net payment. The net payment reflects a milestone payment of $10.0 million to the Company from Maruho, offset by a $7.5 million payment to Dermira, Inc., pursuant to the terms of the Qbrexza Agreement between the Company and Dermira. The nine-month period ended September 30, 2022 also reflects total year-to-date royalties of $129,000 from Maruho on sales of Rapifort® Wipes 2.5% in Japan.

Gross-to-Net Sales Accruals

We record gross-to-net sales accruals for chargebacks, distributor service fees, prompt pay discounts, sales returns, coupons, managed care rebates, government rebates, and other allowances customary to the pharmaceutical industry. For a discussion of our gross-to-net sales accruals, see “Critical Accounting Estimates and Significant Accounting Policies” in the 2021 Form 10-K.

Gross-to-net sales accruals and the balance in the related allowance accounts for the three-month periods ended September 30, 2022, and 2021 were as follows:

($’s in thousands)

​ ​ ​ ​ ​ ​ ​ ​ ​ Chargebacks and Distributor Service Fees ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Returns ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Coupons ​ ​ ​ ​ ​ ​ ​ Managed Care Rebates ​ ​ ​ ​ ​ ​ ​ ​ Gov’t Rebates ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total
Balance as of December 31, 2021 ​ $1,610 ​ $3,240 ​ $4,992 ​ $3,492 ​ $690 ​ $14,024
Current provision related to sales in the current period ​ ​ 7,132 ​ 3,996 ​ 92,330 ​ 17,131 ​ 2,395 ​ 122,984
Checks/credits issued to third parties ​ ​ (7,324) ​ (4,274) ​ (95,370) ​ (16,874) ​ (2,156) ​ (125,998)
Reclassifications between liability accounts ​ ​ — ​ — ​ — ​ — ​ — ​ —
Balance as of September 30, 2022 ​ $1,418 ​ $2,962 ​ $1,952 ​ $3,749 ​ $929 ​ $11,010

($’s in thousands)

​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Chargebacks and Distributor Service Fees ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Returns ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Coupons ​ ​ ​ ​ ​ ​ ​ ​ Managed Care Rebates ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Gov’t Rebates ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total
Balance as of December 31, 2020 ​ $— ​ $2,580 ​ $12,769 ​ $100 ​ $— ​ $15,449
Current provision related to sales in the current period ​ — ​ 3,374 ​ 105,818 ​ 5,072 ​ 803 ​ 115,067
Checks/credits issued to third parties ​ — ​ (1,987) ​ (112,345) ​ (2,939) ​ (163) ​ (117,434)
Reclassifications between liability accounts ​ — ​ (315) ​ 315 ​ — ​ — ​ —
Balance as of September 30, 2021 ​ $— ​ $3,652 ​ $6,557 ​ $2,233 ​ $640 ​ $13,082

We have established provisions for chargebacks resulting from the launch of our new products noted above. Included in the reserve for chargebacks and distributor service fees are provisions for prompt pay discounts.

Our provision for returns was $3.0 million at September 30, 2022, compared to $3.2 million at December 31, 2021. The decrease is primarily due to lower sales for certain products.

The provision for coupons was $2.0 million at September 30, 2022 compared to $5.0 million at December 31, 2021. The decrease is primarily due to the decrease in sales specifically for Targadox, as a result of continued generic competition and to a lesser extent, the timing of payments from December 31, 2021.

Our managed care rebate provision was $3.7 million at September 30, 2022 compared to $3.5 million at December 31, 2021. The increase is primarily due to incremental provisions resulting from our newly launched products, Qbrexza, acquired and launched during the second quarter of 2021, as well as the acquisition and launch of Amzeeq and Zilxi in January 2022, and to a lesser extent, a greater portion of sales qualifying for managed care rebates.

Our government rebate provision was $0.9 million at September 30, 2022 compared to $0.7 million at December 31, 2021. The increase is primarily due to incremental provisions resulting from the acquisitions of Amzeeq and Zilxi in January 2022.

Cost of Goods Sold

Cost of goods sold increased by $0.5 million, or 2%, to $23.1 million for the nine-month period ended September 30, 2022, from $22.6 million for the nine-month period ended September 30, 2021. The increase is primarily due to higher product cost of goods sold of $2.1 million driven by our increased net product sales from period-to-period, increased amortization of $1.1 million related to our acquired intangible assets from the acquisition of Amzeeq and Zilxi in January 2022, and costs of approximately $1.1 million related to freight, product validation and stability testing for Amzeeq and Zilxi. The above increases to cost goods sold from period-to-period are offset, in part, by a decrease as the nine-month period ended September 30, 2021 included an inventory step-up of $4.2 million for inventory units sold related to the acquired finished goods of Qbrexza in 2021.

Research and Development

Research and Development expense increased to $6.7 million for the nine-month period ended September 30, 2022 from $0.8 million for the nine-month period ended September 30, 2021. The increase is related to clinical trial expenses to develop our DFD-29 product, for which dosing began in March 2022. We expect these expenses to increase as additional patients are enrolled into the two Phase 3 trials as well as the other associated cost of the development program.

Research and Development - licenses acquired

Research and development expenses - licenses acquired decreased $13.8 million, or 100%, from the nine-month period ended September 30, 2021. The nine-month period ended September 30, 2021 reflects the acquisition of our development stage asset from DRL for $10.0 million and the fair value of the contingent payment due DRL of $3.8 million.

Selling, General and Administrative

Selling, general and administrative expenses increased $20.1 million, or 84%, to $45.5 million for the nine-month period ended September 30, 2022, from $24.8 million for the nine-month period ended September 30, 2021. The increase is primarily attributable to the expansion of our salesforce, marketing expenses related to the expanded product portfolio of our four products, additional headcount costs, including non-cash stock compensation expenses, legal expenses and compliance and other professional fees associated with being a public company.

Interest Expense

Interest expense decreased $1.5 million to $1.4 million for the nine-month period ended September 30, 2022, from $2.9 million for the nine-month period ended September 30, 2021. The nine-month period ended September 30, 2021 includes dividends and interest on our convertible preferred shares that converted into common stock upon the closing of our IPO in November 2021.

Income tax expense (benefit)

For the nine-month period ended September 30, 2022, income taxes reflected an income tax expense of $50,000. For the nine-month period ended September 30, 2021, income taxes reflected an income tax benefit of $6.7 million. The change in our income tax benefit from the year-ago period is due to changes in unfavorable permanent book-tax differences and a full valuation allowance against the Company’s deferred tax.

Liquidity and Capital Resources

At September 30, 2022, we had $34.9 million in cash and cash equivalents as compared to $49.1 million at December 31, 2021.

On November 16, 2021, we completed an IPO of our Common Stock, which resulted in net proceeds of approximately $30.6 million, after deducting underwriting discounts and other offering costs.

Prior to our IPO, our operations were primarily financed through a working capital note from Fortress, referred to herein as the “Fortress Note,” cash generated by operations and cash raised in our private offering of our Class A Preferred Stock. In connection with the closing of our IPO on November 16, 2021, we issued 2,231,346 shares of Common Stock resulting from the conversion of all of the Class A Preferred Stock. In addition, the Fortress Note was converted into 1,610,467 shares of Journey Common Stock at our IPO price of $10.00 per share.

On January 12, 2022, we entered into a third amendment of the loan and security agreement with EWB (the “Amendment”), which increased the borrowing capacity of our revolving line of credit to $10.0 million and added a term loan not to exceed $20.0 million. Both the revolving line of credit and the term loan mature on January 12, 2026. In January 2022 and August 2022, the Company borrowed $15.0 million and $5.0 million, respectively, against the term loan. The term loans bear interest at a floating rate equal to 1.73% above the prime rate and are payable monthly. The term loans contain an interest-only payment period through January 12, 2024, with an extension through July 12, 2024 if certain covenants are met, after which the outstanding balance of each term loan is payable in equal monthly installments of principal, plus all accrued interest, through the term loan maturity date. We may elect to prepay all or any part of the term loan without penalty or premium, but we may not re-borrow any amount, once repaid. Any outstanding borrowing against the revolving line of credit bears interest at a floating rate equal to 0.70% above the prime rate. The Amendment includes customary financial covenants such as collateral ratios and minimum liquidity provisions. We are in compliance with all applicable financial covenants under the Amendment. The $10.0 million revolving line of credit is fully available to us without any restrictions, other than certain customary and ordinary closing conditions.

We expect that our expenses will increase substantially for the foreseeable future as we pursue business development opportunities, commercialize and market new products and incur additional costs associated with operating as a public company. To date, our business has not been materially impacted by COVID-19; however, depending on the extent of the ongoing pandemic, it is possible that our business, financial condition and results of operations could be materially and adversely affected by COVID-19 in the future. Additionally, the Federal Reserve has raised and is expected to continue to raise the federal funds interest rate throughout 2022 in its effort to take action against domestic inflation. Because our borrowings under the facility with EWB bear interest at a floating rate, rising interest rates affect the amount of the regular payments we are required to make to EWB. Accordingly, we may experience materially higher borrowing costs in future fiscal quarters than we historically have to date. We may require additional financing to pursue both development stage and commercial opportunities. In addition, we anticipate increased commercialization expenses related to the launch of newly acquired products, as well as increased costs related to development and regulatory approval of potential development stage product acquisitions, including DFD-29. As we continue to expand our product portfolio, we may need to fund possible future operating losses, and, if deemed appropriate, establish or secure through additional third-party manufacturing for our products, and expanded sales and marketing capabilities related to recent product acquisitions. For the next twelve months from the issuance of the financial statements included in this report, we will be able to fund our operations through a combination of existing cash and cash equivalents, cash generated from operations and the EWB borrowing facility. Our failure to raise capital as and when needed would have a material adverse impact on our financial condition and our ability to pursue our business strategies.

Cash Flows for the Nine-Month Periods Ended September 30, 2022 and 2021

($’s in thousands)

​ ​ ​ ​ ​ ​ ​ ​ Nine-month periods ended September 30, 2022 ​ ​ ​ 2021 ​ ​ ​ ​ ​ ​ Increase (Decrease)
Net cash (used in) provided by operating activities ​ $(9,698) ​ $1,025 ​ $10,733
Net cash used in investing activities ​ (20,000) ​ (8,800) ​ 11,200
Net cash provided by financing activities ​ 15,508 ​ 21,218 ​ (5,710)
Net change in cash and cash equivalents ​ ​ (14,190) ​ ​ 13,443 ​ ​ 27,643

Operating Activities

Our cash flows from operating activities reflect the cash receipts and disbursements from all activities other than investing and financing activities. Our changes in cash from operating activities reflect the timing of cash collections from our customer; payments to vendors, suppliers, employees; our receipt of customer discounts and rebates; and other customary payments made in the ordinary course of business.

Net cash used in operating activities increased by $10.7 million, to $9.7 million for the nine-month period ended September 30, 2022, from net cash provided by operations of $1.0 million for the nine-month period ended September 30, 2021. The increase in cash used in operating activities was driven primarily by vendor, supplier, and other payments in the ordinary course of business, which were generally higher as a result of additional headcount costs, marketing expenses related to our expanded product portfolio, legal expenses and compliance and other costs associated with being a public company, offset by accounts receivable cash collections.

Investing Activities

Our cash used for investing activities reflects cash used for acquisitions of products and licenses.

Net cash used in investing activities increased by $11.2 million, to $20.0 million for the nine-month period ended September 30, 2022, from $8.8 million for the nine-month period ended September 30, 2021. Net cash used in investing activities increased by $11.2 million primarily due to the $20.0 million consideration paid to Vyne pursuant to the Vyne Product Acquisition Agreement during the nine-month period ended September 30, 2022 as compared to payments of $8.8 million for research and development licenses during the nine-month period ended September 30, 2021.

Financing Activities

Our financing activities include cash used to pay licenses installments, debt and other borrowings, reduced by proceeds from the exercise of stock options and issuance of long-term debt and other borrowings.

Net cash provided by financing activities decreased $5.7 million, to $15.5 for the nine-month period ended September 30, 2022, from $21.2 million for the nine-month period ended September 30, 2021. The decrease is primarily related to approximately $8.1 million of lower net borrowings compared to the prior-year period, offset by lower license installment payments of $2.3 million from period-to-period.

Material Cash Requirements

In the normal course of business, we enter into contractual obligations that contain cash requirements of which the most significant to date include the following:

  • Our loan and security agreement with EWB was recently amended to increase the borrowing capacity of our revolving line of credit to $10.0 million and to add a term loan not to exceed $20.0 million. Both the revolving line of credit and the term loan mature on January 12, 2026. On January 12, 2022, we borrowed $15.0 million against the first tranche of the term loan to facilitate the Vyne Product Acquisition Agreement. On August 2, 2022 the Company borrowed the additional $5.0 million under the second tranche of the term loan. The term loans bear interest at a floating rate equal to 1.73% above the prime rate and interest is payable monthly. The term loan contains an interest-only payment period through January 12, 2024, with an

extension through July 12, 2024 if certain covenants are met, after which the outstanding balance of each term loan is payable in equal monthly installments of principal, plus all accrued interest, through the term loan maturity date. We may prepay all or any part of the term loan without penalty or premium, but may not re-borrow any amount, once repaid. Any outstanding borrowing against the revolving line of credit bears interest at a floating rate equal to 0.70% above the prime rate. Based on the amount currently outstanding under the EWB facility and current interest rates, we expect to make the following payments:

($’s in thousands)

​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Payments by Period ​ ​ Total ​ ​ ​ ​ Remainder of 2022 ​ ​ ​ ​ ​ ​ 2023 ​ ​ ​ ​ ​ ​ 2024 ​ ​ ​ ​ ​ ​ 2025 ​ ​ ​ ​ ​ ​ 2026
Interest ​ $4,635 ​ $433 ​ $1,770 ​ $1,693 ​ $735 ​ $4
Principal ​ 20,000 ​ ​ — ​ ​ — ​ 5,556 ​ 13,333 ​ 1,111
Total ​ $24,635 ​ $433 ​ $1,770 ​ $7,249 ​ $14,068 ​ $1,115

Should we elect to make further borrowings under the EWB facility, we would expect to repay additional amounts in each year until maturity.

  • Pursuant to the Vyne Product Acquisition Agreement, upon the one year anniversary of the closing, January 12, 2023, we agreed to pay to Vyne an additional $5.0 million, constituting the full purchase price. Upon the achievement of net sales milestones with respect to the products purchased in the Vyne Product Acquisition, we are also required to pay contingent consideration consisting of a one-time payment, per product, of $10 million, $20 million, $30 million, $40 million and $50 million upon each product reaching annual net sales of $100 million, $200 million, $300 million, $400 million and $500 million, respectively. Each required payment must only be paid one time following the first achievement of the applicable annual net sales milestone amount.
  • Pursuant to the DFD-29 Agreement with DRL, we paid an upfront payment of $10.0 million. Additional contingent regulatory and commercial milestone payments totaling up to $158.0 million may also be payable. Royalties ranging from ten percent to twenty percent are payable on net sales of the product. Additionally, we are required to fund and oversee the Phase 3 clinical trials approximating $24.0 million, based upon the current development plan and budget.
  • We are contractually obligated to make installment milestone payments on our acquired licenses as follows:

($’s in thousands)

​ ​ ​ Product ​ ​ ​ ​ ​ ​ Payments by Period ​ ​ Total ​ ​ ​ ​ Remainder of 2022 ​ ​ ​ ​ ​ ​ 2023 ​ ​ ​ ​ ​ ​ 2024
Ximino ​ $5,000 ​ $2,000 ​ $1,500 ​ $1,500
Accutane ​ 1,000 ​ — ​ 1,000 ​ —
Total ​ $6,000 ​ $2,000 ​ $2,500 ​ $1,500
  • We are contractually obligated to make sales-based royalty payments to Dermira, Inc. (for Qbrexza), Sun Pharmaceutical Industries (for Exelderm and Ximino) and PuraCap Caribe (for Targadox). Due to the contingent nature of these obligations, the amounts of these payments cannot be reasonably predicted.

Market risk

As filed, 163 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise required under this item.

Controls and procedures

As filed, 1,322 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness, as of September 30, 2022, of the design and operation of our disclosure controls and procedures, as such term is defined in Exchange Act Rules 13a-15(e) and 15d-15(e). Based on this evaluation, our principal executive officer and principal financial officer have concluded that, as of such date, our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in our Exchange Act reports is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

No change in internal control over financial reporting occurred during the most recent quarter with respect to our operations, which materially affected, or is reasonable likely to materially affect, our internal controls over financial reporting.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2022-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2022-07-01 to 2022-09-30$16.0mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue9 months2022-01-01 to 2022-09-30$55.1mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2022-07-01 to 2022-09-30$7.2mus-gaap:CostOfRevenue
Cost of revenue9 months2022-01-01 to 2022-09-30$23.1mus-gaap:CostOfRevenue
Research and development3 months2022-07-01 to 2022-09-30$2.8mus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2022-01-01 to 2022-09-30$6.7mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2022-07-01 to 2022-09-30$15.6mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative9 months2022-01-01 to 2022-09-30$45.5mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2022-07-01 to 2022-09-30−$9.5mus-gaap:OperatingIncomeLoss
Operating income9 months2022-01-01 to 2022-09-30−$17.5mus-gaap:OperatingIncomeLoss
Interest expense3 months2022-07-01 to 2022-09-30$559.0kus-gaap:InterestExpense
Interest expense9 months2022-01-01 to 2022-09-30$1.4mus-gaap:InterestExpense
Income tax3 months2022-07-01 to 2022-09-30$10.0kus-gaap:IncomeTaxExpenseBenefit
Income tax9 months2022-01-01 to 2022-09-30$50.0kus-gaap:IncomeTaxExpenseBenefit
Net income3 months2022-07-01 to 2022-09-30−$10.1mus-gaap:NetIncomeLoss
Net income9 months2022-01-01 to 2022-09-30−$19.0mus-gaap:NetIncomeLoss
Diluted EPS3 months2022-07-01 to 2022-09-30−$0.57us-gaap:EarningsPerShareDiluted
Diluted EPS9 months2022-01-01 to 2022-09-30−$1.09us-gaap:EarningsPerShareDiluted
Basic EPS3 months2022-07-01 to 2022-09-30−$0.57us-gaap:EarningsPerShareBasic
Basic EPS9 months2022-01-01 to 2022-09-30−$1.09us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2022-07-01 to 2022-09-3017,618,064 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2022-01-01 to 2022-09-3017,464,561 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2022-01-01 to 2022-09-30−$9.7mus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2022-09-30$34.9mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2022-09-30$79.6mus-gaap:AssetsCurrent
Total assetsAt period end2022-09-30$108.1mus-gaap:Assets
Current liabilitiesAt period end2022-09-30$60.8mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2022-09-30$82.0mus-gaap:Liabilities
Long-term debtAt period end2022-09-30$19.8mus-gaap:LongTermDebtNoncurrent
Short-term borrowingsAt period end2022-09-30$0us-gaap:ShortTermBorrowings
Shareholders' equityAt period end2022-09-30$26.2mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001410578-22-003162. Last ingested by Listed: Nov 13, 2026, 16:22 ET. Listed shows no prices and gives no investment advice.